RESULTS	A significantly greater proportion of patients receiving exenatide QW compared with insulin glargine achieved HbA ( 1c ) target levels of 7.0 % ( 89 of 211 [ 42.2 % ] vs 44 of 210 [ 21.0 % ] ) or 6.5 % ( 44 of 214 [ 20.6 % ] vs 9 of 212 [ 4.2 % ] ) at end point ( P < 0.001 for both ) .\